Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objectives: Clinical practice guidelines (CPGs) support the translation of research evidence into clinical practice. Key health questions in CPGs ensure that recommendations will be applicable to the clinical context in which the guideline is used. The objectives of this study were to identify CPGs for the pharmacological treatment of first-episode schizophrenia; assess the quality of these guidelines using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument; and compare recommendations in relation to the key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia. Methods: A multidisciplinary group identified key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia. The MEDLINE and EMBASE databases, websites of professional organisations and international guideline repositories, were searched for CPGs that met the inclusion criteria. The AGREE II instrument was applied by three raters and data were extracted from the guidelines in relation to the key health questions. Results: In total, 3299 records were screened. 10 guidelines met the inclusion criteria. 3 guidelines scored well across all domains. Recommendations varied in specificity. Side effect concerns, rather than comparative efficacy benefits, were a key consideration in antipsychotic choice. Antipsychotic medication is recommended for maintenance of remission following a first episode of schizophrenia but there is a paucity of evidence to guide duration of treatment. Clozapine is universally regarded as the medication of choice for treatment resistance. There is less evidence to guide care for those who do not respond to clozapine. Conclusions: An individual's experience of using antipsychotic medication for the initial treatment of first-episode schizophrenia may have implications for future engagement, adherence and outcome. While guidelines of good quality exist to assist in medicines optimisation, the evidence base required to answer key health questions relevant to the pharmacological treatment of first-episode schizophrenia is limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877 · cited 4×
“The variation in doses suggested reflect the individuality of clozapine use in clinical practice,(24) 28 29 31–33 with the potential for delayed response to clozapine treatment leading to the longer duration of a trial of clozapine of up to 1 year recommended in some guidelines.(26) 28 29 32 The most common strategy s…”
BackgroundMethodInfluentialAlonso-Coello, P., Oxman, A. D., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Vandvik, P. O., Meerpohl, J., et al. (2016) · BMJ · doi:10.1136/bmj.i2089 · Cited by 814
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.19 · Cited by 567
McGorry, P., Bates, T., & Birchwood, M. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.119214 · Cited by 523
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115 · cited 1×
“treatment recommendations have been evaluated by various authors in relation to guidelines that apply to the USA,(19) or the difference in recommendations for single aspects of care such as maintenance treatment.(20) Since guidelines are updated or new guidelines become available, it is important to continue to assess…”
MethodMayoral-van Son, J., de la Foz, V. O.-G., Martinez-Garcia, O., Moreno, T., Parrilla-Escobar, M., Valdizan, E. M., & Crespo-Facorro, B. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09540 · Cited by 60
Research works printed but not linked: 50
- Cowen P , Harrison P , Burns T . Shorter Oxford textbook of psychiatry. Oxford University Press, 2012. · DOI
- 10.1192/bjp.187.48.s116 · DOI · Paper page
- 10.1093/schbul/sbi032 · DOI
- 10.1016/j.eurpsy.2004.06.031 · DOI · Paper page
- Graham R , Mancher M , Wolman DM , et al . Clinical practice guidelines we can trust. National Academies Press, 2011. · DOI · Paper page
- 10.1192/bjp.bp.112.112383 · doi:10.1192/bjp.bp.112.112383
- 10.1111/bdi.12128 · DOI
- 10.1192/bjp.187.3.248 · DOI · Paper page
- 10.3109/09540261.2011.606801 · DOI
- Castellani, 2015, Rigour of development of clinical practice guidelines for the pharmacological treatment of bipolar disorder: systematic review, J Affect Disord, 174, 45, 10.1016/j.jad.2014.11.032 · DOI
- 10.1136/bmjopen-2015-009189 · DOI
- Moore, 2011, Schizophrenia treatment guidelines in the United States, Clin Schizophr Relat Psychoses, 5, 40, 10.3371/CSRP.5.1.6 · DOI
- 10.3109/15622975.2012.696143 · DOI · Paper page
- 10.3109/15622975.2012.739708 · DOI · Paper page
- Hasan, 2015, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation, World J Biol Psychiatry, 16, 142, 10.3109/15622975.2015.1009163 · DOI · Paper page
- 10.1093/schbul/sbp116 · DOI · Paper page
- Barnes, 2011, Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology, J Psychopharmacol (Oxford), 25, 567, 10.1177/0269881110391123 · DOI · Paper page
- Osser, 2013, The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia, Harv Rev Psychiatry, 21, 18, 10.1097/HRP.0b013e31827fd915 · DOI
- 10.1016/S0140-6736(08)60486-9 · DOI · Paper page
- 10.1097/YCO.0b013e32830eb6b4 · DOI · Paper page
- 10.1136/bmj.g3725 · DOI · Paper page
- Mavridis, 2016, Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant, J Clin Epidemiol, 69, 161, 10.1016/j.jclinepi.2015.05.027 · DOI
- Samalin, 2013, Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?, Compr Psychiatry, 54, 309, 10.1016/j.comppsych.2012.10.001 · DOI
- 10.1016/j.schres.2011.04.006 · DOI
- 10.1016/j.schres.2013.07.031 · DOI · Paper page
- 10.1016/j.schres.2012.08.013 · DOI
- 10.1016/j.schres.2016.02.034 · DOI
- 10.1176/appi.ajp.2014.14111465 · DOI
- Hynes, 2015, Glasgow antipsychotic side-effects scale for clozapine—development and validation of a clozapine-specific side-effects scale, Schizophr Res, 168, 505, 10.1016/j.schres.2015.07.052 · DOI
- Haro, 2014, Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship?, Psychiatry Res, 220, 163, 10.1016/j.psychres.2014.07.034 · doi:10.1016/j.psychres.2014.07.034
- 10.1176/appi.ajp.2008.08050756 · DOI · Paper page
- Karson, 2016, Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review, Neuropsychiatr Dis Treat, 12, 57, 10.2147/NDT.S96392 · DOI
- 10.1176/appi.ajp.2012.12060778 · DOI
- Lieberman, 2003, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine, Neuropsychopharmacology, 28, 995, 10.1038/sj.npp.1300157 · DOI · Paper page
- 10.4088/JCP.09m05785yel · DOI · Paper page
- 10.1093/schbul/sbp129 · DOI · Paper page
- Heres, 2014, Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics, Eur Psychiatry, 29, 1409, 10.1016/S0924-9338(14)70001-X · DOI · Paper page
- 10.1093/schbul/18.3.515 · DOI · Paper page
- 10.1001/archpsyc.63.10.1079 · DOI · Paper page
- Stroup, 2014, What is the role of long-acting injectable antipsychotics in the treatment of schizophrenia?, J Clin Psychiatry, 75, 1261, 10.4088/JCP.14com09518 · DOI
- Samara, 2016, Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis, JAMA psychiatry, 73, 199, 10.1001/jamapsychiatry.2015.2955 · DOI · Paper page
- 10.1186/1471-244X-10-8 · DOI · Paper page
- 10.1093/schbul/sbu065 · DOI
- 10.1192/bjp.bp.111.105833 · DOI · Paper page
- Girlanda F , Fiedler I , Becker T , et al . The evidence–practice gap in specialist mental healthcare: systematic review and meta-analysis of guideline implementation studies. Br J Psychiatry 2016. doi:10.1192/bjp.bp.115.179093 · DOI · Paper page
- 10.1176/appi.ajp.2014.13101355 · DOI · Paper page
- 10.4088/JCP.v64n0107 · DOI · Paper page
- Üçok, 2015, Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia, Int Clin Psychopharmacol, 30, 290, 10.1097/YIC.0000000000000086 · DOI
- 10.1097/JCP.0b013e318267b3cd · DOI · Paper page
- Campsall, 2016, Financial relationships between organizations that produce clinical practice guidelines and the biomedical industry: a cross-sectional study, PLoS Med, 13, e1002029, 10.1371/journal.pmed.1002029 · DOI
Cited by
Takeuchi, H., Siu, C., Remington, G., Fervaha, G., Zipursky, R. B., Foussias, G., & Agid, O. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0278-3 · Cited by 200
Recovery from schizophrenia: is it possible?
Vita, A., & Barlati, S. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000407 · Cited by 187
Carolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., Hahn, M. K., Krivoy, A., Lally, J., Leucht, S., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae205 · Cited by 70
Self-citationRotella, F., Cassioli, E., Calderani, E., Lazzeretti, L., Ragghianti, B., Ricca, V., & Mannucci, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.118 · Cited by 48
Schizophrenia and medication adherence: Associated factors.
Karabulut, B., & Uslu, E. (2024) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2024.01.015 · Cited by 32
Metadata
- Authors
- Keating, D., McWilliams, S., Schneider, I., Hynes, C., Cousins, G., Strawbridge, J., & Clarke, M.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-01
- Volume
- 7
- Issue
- 1
- Pages
- e013881
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2567911914
- Cited by
- 130
- References
- 10
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. https://app.cochat.ai/papers/10.1136/bmjopen-2016-013881
- The paper
- Keating, D., McWilliams, S., Schneider, I., Hynes, C., Cousins, G., Strawbridge, J., & Clarke, M. (2017). Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. https://doi.org/10.1136/bmjopen-2016-013881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.